

1 **Early signals of significantly increased vaccine**  
2 **breakthrough, decreased hospitalization rates, and less**  
3 **severe disease in patients with COVID-19 caused by the**  
4 **Omicron variant of SARS-CoV-2 in Houston, Texas**

5  
6  
7 Paul A. Christensen,<sup>\*,†,‡,§</sup> Randall J. Olsen,<sup>\*,†,‡,§</sup> S. Wesley Long,<sup>\*,†,‡,§</sup> Richard Snehal,<sup>†</sup>  
8 James J. Davis,<sup>¶,\*\*</sup> Matthew Ojeda Saavedra,<sup>†</sup> Kristina Reppond,<sup>†</sup> Madison N. Shyer,<sup>†</sup>  
9 Jessica Cambric,<sup>†</sup> Ryan Gadd,<sup>†</sup> Rashi M. Thakur,<sup>†</sup> Akanksha Batajoo,<sup>†</sup> Regan  
10 Mangham,<sup>†</sup> Sindy Pena,<sup>†</sup> Trina Trinh,<sup>†</sup> Jacob C. Kinsley,<sup>†</sup> Guy Williams,<sup>†</sup> Robert  
11 Olson,<sup>¶,\*\*</sup> Jimmy Gollihar,<sup>‡</sup> James M. Musser<sup>†,‡,§,††</sup>

12  
13 *\*Contributed equally;*

14 *†Laboratory of Human Molecular and Translational Human Infectious Diseases and*

15 *‡Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for*

16 *Infectious Diseases, Houston Methodist Research Institute and Department of*

17 *Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;*

18 *§Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New*

19 *York, New York;*

20 <sup>¶</sup>*Consortium for Advanced Science and Engineering, University of Chicago, Chicago,*

21 *Illinois;*

22 <sup>\*\*</sup>*Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont,*

23 *Illinois;*

24

25 <sup>††</sup>*Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology*

26 *and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,*

27 *Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:*

28 [jmmusser@houstonmethodist.org](mailto:jmmusser@houstonmethodist.org)

29

30 Running head: Omicron variant in Houston, Texas

31

32 Disclosures: None.

33

34 Funding: This project was supported by the Houston Methodist Academic Institute

35 Infectious Diseases Fund; and in part with funds from the National Institute of Allergy

36 and Infectious Diseases, National Institutes of Health, Department of Health and Human

37 Services, under Contract No. 75N93019C00076 (J.J.D.).

38

39 Number of text pages: 13

40 Number of figures: 2

41 Number of tables: 2

42 **Abstract**

43 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the  
44 COVID-19 pandemic. The recently described variant of concern designated Omicron  
45 (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of  
46 COVID-19 cases in many countries. Because Omicron was recognized very recently,  
47 many knowledge gaps exist about its epidemiology, clinical severity, and disease  
48 course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston  
49 Methodist healthcare system identified 1,313 symptomatic patients with infections  
50 caused by Omicron from late November 2021 through December 20, 2021. Omicron  
51 very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases.  
52 Compared to patients infected with either Alpha or Delta variants in our healthcare  
53 system, Omicron patients were significantly younger, had significantly increased  
54 vaccine breakthrough rates, and were significantly less likely to be hospitalized.  
55 Omicron patients required less intense respiratory support and had a shorter length of  
56 hospital stay, consistent with decreased disease severity. Although the number of  
57 Omicron patients we studied is relatively small, in the aggregate the data document the  
58 unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron  
59 variant in metropolitan Houston, and provide information about disease character.

60

61

62

63 [Introduction]

64  
65  
66 Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-  
67 CoV-2 have caused two distinct COVID-19 disease surges in the United States,  
68 Southeast Asia, Europe, and elsewhere ([https://www.cdc.gov/coronavirus/2019-  
69 ncov/cases-updates/variant-surveillance/variant-info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)), last accessed December 30,  
70 2021; <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed  
71 December 30, 2021)<sup>1</sup>, and remodeled the landscape of human behavior and many  
72 societies. Delta replaced the Alpha variant as the cause of virtually all COVID-19 in  
73 many countries ([https://www.who.int/publications/m/item/weekly-epidemiological-  
74 update-on-covid-19---13-july-2021](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-july-2021)), last accessed August 18, 2021;  
75 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions  
76 anddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/coronaviruscovid19infectionsurveyspilot/9july2021), last accessed  
77 August 18, 2021).

78 At the start of the pandemic almost two years ago, the Houston Methodist  
79 healthcare system instituted a comprehensive and integrated population genomics  
80 project designed to sequence all SARS-CoV-2 samples causing COVID-19 in patients  
81 cared for at our facilities, which include eight hospitals located throughout the  
82 metroplex. The project was implemented when the initial Houston Methodist COVID-19  
83 case was diagnosed at the end of February 2020, and has continued unabated<sup>2-6</sup>. This  
84 project was facilitated by the existence of a single large diagnostic laboratory that  
85 serves the entire system and is seamlessly integrated with a research institute with  
86 extensive genomics expertise and capacity. A key goal was to comprehensively map  
87 the population genomics, trajectory, and other features of the pandemic in metropolitan

88 Houston with a population size of approximately 7.2 million. Houston is the fourth  
89 largest city in the United States, the most ethnically diverse metropolitan area in the  
90 country, and is a major port of entry. To date, SARS-CoV-2 genomes have been  
91 sequenced from greater than 70,000 patient samples. Many features of four distinct  
92 SARS-CoV-2 waves in Houston have been described<sup>2-6</sup>.

93         The successes of rapid SARS-CoV-2 vaccine development and documented  
94 efficacy, coupled with the significant downturn of the disease wave caused by Delta in  
95 Houston and elsewhere in fall, 2021<sup>6</sup>, suggested that the pandemic was abating.  
96 However, the identification of a new VOC designated B.1.1.529 and commonly known  
97 as Omicron that has spread rapidly in South Africa and the UK has tempered this  
98 optimism<sup>7-9</sup>. Inasmuch as Omicron was recognized very recently, and much is not  
99 known about its epidemiology and clinical characteristics and course, we used our  
100 integrated infrastructure in an effort to address some pertinent knowledge gaps.  
101 Genome sequencing identified 1,313 COVID-19 patients with symptomatic disease  
102 caused by Omicron in the Houston Methodist healthcare system beginning in late  
103 November 2021 and ending December 20, 2021. In three weeks Omicron spread  
104 throughout the Houston metropolitan region and became the cause of 90% of new  
105 COVID-19 cases. Although the number of our Omicron patients is relatively small,  
106 compared to patients infected with either Alpha or Delta variants and cared for in our  
107 system, significantly fewer Omicron patients were hospitalized, and those who were  
108 hospitalized required significantly less intense respiratory support and had a shorter  
109 length of stay. We cautiously interpret our findings to be consistent with decreased  
110 disease severity among Houston Methodist Omicron patients. Many factors undoubtedly

111 have contributed, including but not limited to increased vaccination uptake, population  
112 immunity, and patient demographics such as younger age. The extent to which our  
113 findings translate to other cities and other patient populations, including children, is  
114 unknown. Our study was not designed to address possible intrinsic differences in  
115 virulence of Omicron compared to Alpha, Delta, and other VOCs. We believe this topic  
116 remains an open question that warrants further investigation.

117

118

## 119 **Materials and Methods**

120

### 121 **Patient Specimens**

122

123 Specimens were obtained from patients registered at Houston Methodist facilities (e.g.,  
124 hospitals and urgent care centers), and institutions in the Houston metropolitan region  
125 that use our laboratory services. The great majority of individuals had signs or  
126 symptoms consistent with COVID-19 disease. For analyses focusing on patients with  
127 COVID-19 caused by the Omicron variant, samples obtained from November 27, 2021  
128 through December 20, 2021 were used. This time frame was chosen because it  
129 represents the period during which an Omicron variant was first identified in our  
130 healthcare system and the last date of specimen collection used to generate genome  
131 sequence data for this manuscript. For analyses comparing features of patients infected  
132 with the Omicron VOC and Alpha and Delta VOCs, all patients documented to be

133 infected with these variants in the Houston Methodist system were studied. The study  
134 included 36,793 unique patients identified in this time frame for whom we had SARS-  
135 CoV-2 genome sequences. The work was approved by the Houston Methodist  
136 Research Institute Institutional Review Board (IRB1010-0199).

137

## 138 SARS-CoV-2 Molecular Diagnostic Testing

139

140 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease  
141 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital  
142 using assays granted Emergency Use Authorization (EUA) from the FDA  
143 ([https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-  
144 diagnostic-testing-sars-cov-2#offeringtests](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2#offeringtests), last accessed June 7, 2021). Multiple  
145 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with  
146 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid  
147 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the Cobas SARS-  
148 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay  
149 using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic  
150 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,  
151 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were  
152 performed on material obtained from nasopharyngeal swabs immersed in universal  
153 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or  
154 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

155 collection methods were used (<https://vimeo.com/396996468/2228335d56>, last  
156 accessed June 7, 2021).

157

158 SARS-CoV-2 Genome Sequencing, Genome Analysis, and Identification of  
159 Variants

160

161 We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston  
162 Methodist healthcare system during the period studied. Libraries for whole SARS-CoV-2  
163 genome sequencing were prepared according to version 4  
164 (<https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312>, last  
165 accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-  
166 automated workflow used has been described previously<sup>2-6</sup>. Sequence reads were  
167 generated with an Illumina NovaSeq 6000 instrument.

168       Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service  
169 (<https://www.bv-brc.org/app/ComprehensiveSARS2Analysis>, last accessed June 7,  
170 2021, requires registration). The pipeline currently uses seqtk version 1.3-r117 for  
171 sequence trimming (<https://github.com/lh3/seqtk.git>) and minimap version 2.17 for  
172 aligning reads against the Wuhan-Hu-1 (NC\_045512.2) reference genome. Samtools  
173 version 1.11 was used for sequence and file manipulation, where maximum depth and  
174 minimum depth parameters in mpileup were set to 8,000 and 3, respectively. iVar  
175 version 1.3.1 was used for primer trimming and variant calling. Genetic lineages,  
176 VOCs, and variants of interest (VOIs) were identified based on genome sequence data  
177 and designated by Pangolin v. 3.1.17 with pangoLEARN module 2021-12-06



178 (<https://cov-lineages.org/resources/pangolin.html>, last accessed December 12, 2021).

179 Genome data used in this study have been deposited to GISAID [www.gisaid.org](http://www.gisaid.org).

180

## 181 S-Gene Target-Failure Assay

182

183 An S-gene target-failure (SGTF) assay (TaqPath COVID-19 Combo Kit Thermo Fisher,  
184 Inc.), was used as a surrogate marker for the Omicron VOC for some specimens  
185 collected between December 18, 2021 and December 22, 2021. From November 1,  
186 2021 onward, only Delta and Omicron were circulating in metropolitan Houston, as  
187 documented by whole-genome sequence data. Thus, samples with S-gene target failure  
188 were classified as Omicron, whereas samples yielding amplification of the S-gene were  
189 classified as a Delta variant.

190

## 191 Patient Metadata and Geospatial Analysis

192

193 Patient metadata were acquired from the electronic medical record by standard  
194 informatics methods. Figures showing geospatial distribution of spread for Omicron  
195 were generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA)  
196 using patient home address zip codes. A vaccination breakthrough case was defined as  
197 a PCR-positive sample from a patient obtained greater than 14 days after full  
198 vaccination (e.g., both doses of the Pfizer or Moderna mRNA vaccines) was completed.  
199 A booster vaccination breakthrough case was defined as a PCR-positive sample from a  
200 patient obtained greater than 14 days after receiving a third vaccine dose. For some

201 cases, manual chart review was conducted to resolve discrepancies or clarify  
202 ambiguities.

203

204

## 205 **Results**

206

### 207 **Omicron Epidemiologic Wave**

208

209 The first Houston Methodist patient infected with an Omicron variant was identified at  
210 the end of November 2021, a time when the Delta VOC was responsible for all COVID-  
211 19 cases in metropolitan Houston<sup>6</sup>. During this period, the metropolitan area was  
212 experiencing a steady decrease in total number of new COVID-19 cases (**Figure 1**,  
213 **Figure 2**).

214 Omicron increased in frequency unusually rapidly over a three-week period in  
215 December (**Figure 1**, **Figure 2**). By December 20, the genome sequence data showed  
216 that Omicron accounted for >90% of all new COVID-19 cases in our healthcare system  
217 (**Figure 2**). This represents the fifth wave of COVID-19 cases in metropolitan Houston  
218 (**Figure 1**). The estimated case doubling time during this three-week period was  
219 approximately 1.8 days (**Figure 2**), which means that Omicron increased in relative  
220 frequency approximately three times faster than Delta had increased in our area<sup>6</sup>, an  
221 unprecedented trajectory for SARS-COV-2 infections.

222 Consistent with extensive infections caused by Omicron in southern Africa and  
223 elsewhere (<https://www.cdc.gov/coronavirus/2019-ncov/variants/variant->

224 [classifications.html](#), last accessed December 28, 2021;  
225 <https://www.gov.uk/government/collections/new-sars-cov-2-variant>, last accessed  
226 December 28, 2021), several patients had very recent travel histories to countries with a  
227 high prevalence of this VOC, suggesting acquisition of virus by some cases from abroad  
228 and importation into Houston. However, the great majority of Omicron patients had no  
229 documented travel outside the US and undoubtedly acquired the infection domestically,  
230 either in Houston or elsewhere.

231 To understand the geospatial distribution of Omicron in metropolitan Houston,  
232 patient metadata were acquired from the electronic medical record by standard  
233 informatics methods, and home address zip codes were used to visualize virus spread  
234 (**Figure 2**). The 1,313 Houston Methodist patients infected with Omicron during this  
235 period were distributed widely throughout metropolitan Houston, with 200 different zip  
236 codes represented (**Figure 2**). The widespread distribution of Omicron in the Houston  
237 metroplex in an extremely short period of time reflects the ability of this variant to spread  
238 unusually rapidly and effectively between individuals, and cause symptomatic disease.

239

## 240 Comparison of Omicron, Alpha, and Delta COVID-19 Cases

241

242 There is a considerable lack of detailed information about patients in the United States  
243 and elsewhere with COVID-19 caused by the Omicron VOC. We compared available  
244 metadata for all Houston Methodist patients infected with Omicron, Alpha, and Delta  
245 VOCs (**Table 1, Table 2**). The populations differed significantly in many characteristics,

246 including median age, hospital admission rates, maximum respiratory support, rate of  
247 vaccine breakthrough, and median length of stay (**Table 1, Table 2**).

248 Patients infected with Omicron were significantly younger than Alpha and Delta  
249 patients (**Table 1, Table 2**). Importantly, Omicron patients were hospitalized significantly  
250 less frequently than patients infected with either the Alpha or Delta variants, and had a  
251 significantly shorter median hospital length of stay (**Table 1, Table 2**).

252 We next analyzed Omicron vaccine breakthrough cases (**Table 1, Table 2**). We  
253 found 675 of the 1313 total Omicron patients (51.4%) for whom we have whole genome  
254 sequence data met the CDC definition of vaccine breakthrough cases (**Table 1, Table**  
255 **2**). There was no simple relationship between the time elapsed since administration of  
256 the second vaccination dose and the date of vaccination breakthrough. These 675  
257 patients received either two doses of the Pfizer-BioNTech BNT162b2 ( $n = 485$ , 72%) or  
258 Moderna mRNA-1273 ( $n = 157$ , 23%), or one dose of J&J/Janssen JNJ-78436735 ( $n =$   
259  $33$ , 5%) vaccine. This distribution reflects the majority use of BNT162b2 vaccination  
260 doses in our health system. Compared to either Alpha or Delta patients, a significantly  
261 greater percentage of patients with breakthrough cases was caused by the Omicron  
262 VOC (51.4% compared to 3.2% and 24.3% for Alpha and Delta VOCs, respectively)  
263 (**Table 1, Table 2**). We next analyzed individuals with breakthrough cases after  
264 receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or Moderna  
265 mRNA-1273 vaccine. We found that 140 (10.7%) of the 1,313 Omicron patients met this  
266 criteria. Consistent with Omicron causing a significantly increased number of vaccine  
267 breakthrough cases, it has been reported that this variant has reduced sensitivity to

268 antibody neutralization *in vitro*, likely in large part due to the extensive number of amino  
269 acid and other structural changes occurring in Omicron spike protein<sup>10-31</sup>.

270

## 271 An Omicron Sublineage With Spike Protein Polymorphism L452R

272

273 The L452R amino acid change in spike protein of SARS-CoV-2 has arisen by  
274 convergent evolution in multiple genetic lineages throughout the course of the  
275 pandemic, most notably in the Delta VOC. L452R is located in the receptor binding  
276 domain of spike protein and has been associated with decreased antibody  
277 neutralization, escape from cell mediated immunity, and increased affinity for the ACE2  
278 receptor<sup>32, 33</sup>. L452R was present in samples of Omicron collected in South Africa as  
279 early as November 11, 2021. We found that all 43 specimens collected over the first  
280 nine days after we identified Omicron in Houston Methodist patients had the 452R  
281 amino acid replacement. Our first L452 isolate was collected on day 10. By day 16, over  
282 half the Omicron isolates collected were L452, and the proportion of 452R isolates  
283 continued to diminish. Among the 65,109 Omicron samples deposited in GISAID as of  
284 28 December 2021, only 727 (1.1%) have the 452R amino acid replacement and over  
285 half of these were from Houston Methodist patients. The initial high prevalence of  
286 Omicron containing 452R in spike protein in our population may represent a founder  
287 effect of the original genotype introduced into Houston.

288

## 289 Spike-Gene Target-Failure Assay

290

291 To estimate Omicron variant frequency in patient samples not yet sequenced, we  
292 performed the TaqPath COVID-19 Combo Kit assay (ThermoFisher) on 657 samples  
293 collected from symptomatic patients between December 18, 2021 and December 22,  
294 2021. In total, 604 (91.9%) of patient samples yielded a RT-PCR result with S-gene  
295 target-failure indicative of the Omicron variant. These data are consistent with the  
296 increasing frequency of new cases of COVID-19 caused by Omicron in our population  
297 **(Figure 2)**.

298

### 299 Lack of Omicron Variant BA.2 in Houston Methodist Samples

300

301 The BA.2 Omicron sublineage was first identified in November 2021 in Australia in a  
302 patient who had traveled to South Africa ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/359)  
303 [designation/issues/359](https://github.com/cov-lineages/pango-designation/issues/359); last accessed December 30, 2021). This sublineage does not  
304 have the full set of polymorphisms characteristic of BA.1 (B.1.1.529) and also has  
305 additional mutations unique to it ([https://github.com/cov-lineages/pango-](https://github.com/cov-lineages/pango-designation/issues/361)  
306 [designation/issues/361](https://github.com/cov-lineages/pango-designation/issues/361); last accessed December 30, 2021). One important difference is  
307 that sublineage BA.2 lacks the spike protein deletion at amino acid 69/70 which means  
308 that it will not be detected by the SGTF assay. We inspected all full genome sequences  
309 present in our large database and this sublineage was not present. This includes all  
310 specimens taken from symptomatic patients or asymptomatic individuals. Thus, it is  
311 likely that routine use of an SGTF assay in our population will identify all or virtually all  
312 patients infected with Omicron.

313

## 314 **Discussion**

315

316 In this work, we describe information relevant to the surging Omicron wave in  
317 metropolitan Houston. In three weeks, Omicron was first identified in our population and  
318 rapidly increased to cause 90% of all new COVID-19 cases, with an estimated case  
319 doubling time of 1.8 days. The study was based on genome sequence analysis of 1,313  
320 Omicron samples taken from socioeconomically, geographically, and ethnically diverse  
321 symptomatic patients. Several key findings were made, including (i) the Omicron VOC  
322 rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an  
323 unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii)  
324 Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta  
325 VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv)  
326 significantly fewer Omicron patients required hospitalization compared to Alpha and  
327 Delta patients; (v) the median length of stay for hospitalized Omicron patients was  
328 significantly shorter than for Alpha and Delta patients, and consistent with this  
329 observation, the maximum respiratory support required for Omicron patients was  
330 significantly less than for Alpha or Delta patients. Our findings are largely consistent  
331 with many aspects of Omicron data reported from the UK, South Africa, and Canada<sup>7-9</sup>,  
332 <sup>34-36</sup> and are consistent with experimental animal infection data suggesting that Omicron  
333 causes less severe disease in mice and hamsters<sup>37-40</sup>. This study was facilitated by a  
334 comprehensive and integrated population genomics and epidemiology project<sup>2-6</sup>  
335 implemented at the end of February, 2020, when the initial COVID-19 case was  
336 diagnosed in the Houston Methodist healthcare system.

337           Because we sequence the genome of approximately 90% of SARS-CoV-2  
338 causing COVID-19 in our diverse Houston Methodist patient population, and have done  
339 so for almost two years, this means we are continuously monitoring the composition of  
340 this virus in a major US metroplex. This affords us the opportunity to rapidly assess  
341 changes in SARS-CoV-2 population genomic structure in the fourth largest city in the  
342 US. However, our study has several limitations. Although we sequenced the genomes  
343 of SARS-CoV-2 causing 90% of all Houston Methodist COVID-19 cases in the study  
344 period, this sample represents only approximately 5% of cases reported in the  
345 metropolitan region. Our patient population will underrepresent some demographic  
346 groups, for example homeless individuals and pediatric patients. The samples  
347 sequenced in this study were obtained from symptomatic individuals, which means that  
348 it is possible that we failed to identify Omicron subvariants or features preferentially  
349 represented in asymptomatic individuals. It is likely that our study included some  
350 patients where Omicron was detected on hospital admission but was incidental to the  
351 primary cause of admission.

352           In the aggregate, our data add critical new information to features of Omicron  
353 genomic epidemiology and patient characteristics in the US. Further, the present study  
354 highlights the importance of analyzing SARS-CoV-2 genome data integrated with  
355 patient metadata and stresses the need to continue to do this in near-real time as the  
356 Omicron surge continues, the virus evolves, and new variants with potentially altered  
357 fitness and biomedically relevant phenotypes are generated. Analyses of this type are  
358 also important in the context of vaccine formulation and long COVID, an increasing  
359 health and economic problem globally. Finally, the strategy we have used in this and



360 previous studies<sup>2-6</sup> are readily applicable to future infectious diseases problems that  
361 warrant special attention.

362

## 363 **Acknowledgments**

364

365 We thank Drs. Marc Boom and Dirk Sostman for their ongoing support, and Dr. Sasha  
366 M. Pejerrey for editorial contributions. The research was supported by the Houston  
367 Methodist Academic Institute Infectious Diseases Fund and many generous Houston  
368 philanthropists. The funders had no role in the design and conduct of the study;  
369 collection, management, analysis, and interpretation of the data; preparation, review, or  
370 approval of the manuscript; and decision to submit the manuscript for publication.

371

372 We declare that we have no conflict of interest.

373

374

## 375 **Author Contributions**

376

377 P.A.C., R.J.O., S.W.L., and J.M.M. had full access to all study data and take  
378 responsibility for the integrity of the data and the accuracy of the data analysis; concept  
379 and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or  
380 interpretation by all authors; drafting of the manuscript by all authors; statistical analysis

381 by P.A.C.; funding obtained by J.M.M. and J.J.D.; and overall supervision by J.M.M.

382 P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

383

384

## 385 **References**

- 386 [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhojar RC, et al.:  
387 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in  
388 Delhi, India. medRxiv 2021. [Preprint]. doi:2021.2006.2002.21258076
- 389 [2] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M,  
390 Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G,  
391 Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS,  
392 Chou CW, Javanmardi K, Finkelstein IJ, Musser JM: Molecular Architecture of Early  
393 Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major  
394 Metropolitan Area. mBio 2020, 11
- 395 [3] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J:  
396 Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in  
397 Houston, TX, revealed by 8,857 genome sequences. medRxiv 2021. [Preprint].  
398 doi:2021.2003.2016.21253753
- 399 [4] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,  
400 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd  
401 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of  
402 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,  
403 Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol  
404 2021, Oct;191(10):1754-1773.
- 405 [5] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,  
406 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,  
407 Musser JM: Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston

408 Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple  
409 Isolates of All Major Variants of Concern. *Am J Pathol* 2021, Jun;191(6):983-992  
410 [6] Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, Walley DR,  
411 Kinskey JC, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur  
412 RM, Batajoo A, Mangham R, Pena S, Trinh T, Yerramilli P, Nguyen M, Olson R, Snehal  
413 R, Gollihar J, Musser JM: Delta Variants of SARS-CoV-2 Cause Significantly Increased  
414 Vaccine Breakthrough COVID-19 Cases in Houston, Texas. *Am J Pathol* 2021, Nov  
415 11;S0002-9440(21)00480-6.

416 [7] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Lessells RJ, et al.: Rapid  
417 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *medRxiv*  
418 2021. [Preprint]. doi:2021.2012.2019.21268028

419 [8] Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J,  
420 Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W,  
421 Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA: Rapid increase  
422 in Omicron infections in England during December 2021: REACT-1 study. *medRxiv*  
423 2021. [Preprint]. doi:2021.2012.2022.21268252

424 [9] Sheikh AK, Steven; Woolhouse, Mark; McMenamin, Jim; Robertson, Chris. : Severity  
425 of Omicron variant of concern and vaccine effectiveness against symptomatic disease:  
426 national cohort with nested test negative design study in Scotland. The University of  
427 Edinburgh 2021

428 [10] Meng B, Ferreira I, Abdullahi A, Kemp SA, Goonawardane N, Papa G, Fatihi S,  
429 Charles O, Collier D, Collaboration C-NBC-, Consortium TGtPJ, Choi J, Hyeon Lee J,  
430 Mlcochova P, James L, Doffinger R, Thukral L, Sato K, Gupta RK: SARS-CoV-2

431 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv 2021.  
432 [Preprint]. doi:2021.2012.2017.473248

433 [11] Zeng C, Evans JP, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T,  
434 Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu S-L:  
435 Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv 2021. [Preprint].  
436 doi:2021.2012.2016.472934

437 [12] Jacobsen H, Strengert M, Maass H, Ynga Durand MA, Kessel B, Harries M, Rand  
438 U, Abassi L, Kim Y, Lueddecke T, Hernandez P, Ortmann J, Heise J-K, Castell S,  
439 Gornyk D, Gloeckner S, Melhorn V, Lange B, Dulovic A, Haering J, Junker D,  
440 Schneiderhan-Marra N, Poehlmann S, Hoffmann M, Krause G, Cicin-Sain L: Diminished  
441 neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-  
442 based COVID-19 vaccinations. medRxiv 2021. [Preprint].  
443 doi:2021.2012.2021.21267898

444 [13] Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck  
445 B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CBEM, Knol MJ:  
446 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated  
447 and previously infected individuals, the Netherlands, 22 November to 19 December  
448 2021. medRxiv 2021. [Preprint]. doi:2021.2012.2020.21268121

449 [14] Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-  
450 Gardner ME, Mantus G, Nyhoff LE, Bechnack S, Alaaeddine G, Naji A, Samaha H, Lee  
451 M, Bristow L, Hussaini L, Ciric CR, Nguyen P-V, Gagne M, Roberts-Torres J, Henry AR,  
452 Godbole S, Grakoui A, Sexton M, Piantadosi A, Waggoner JJ, Douek DC, Anderson EJ,  
453 Roupheal N, Wrammert J, Suthar MS: mRNA-1273 and BNT162b2 mRNA vaccines

454 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv  
455 2021. [Preprint]. doi:2021.2012.2020.473557

456 [15] Zou j, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, Ren P, Shi P-Y:  
457 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.  
458 bioRxiv 2021. [Preprint]. doi:2021.2012.2020.473584

459 [16] Ikemura N, Hoshino A, Higuchi Y, Taminishi S, Inaba T, Matoba S: SARS-CoV-2  
460 Omicron variant escapes neutralization by vaccinated and convalescent sera and  
461 therapeutic monoclonal antibodies. medRxiv 2021. [Preprint].  
462 doi:2021.2012.2013.21267761

463 [17] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T,  
464 Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR,  
465 group tC-Cs: Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by  
466 post-immunisation serum. medRxiv 2021. [Preprint]. doi:2021.2012.2010.21267534

467 [18] Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al.: Broadly  
468 neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv 2021.  
469 [Preprint]. doi:2021.2012.2012.472269

470 [19] Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair  
471 MS, Yu J, Chik KK-H, Yuen TT-T, Yoon C, To KK-W, Chen H, Yin MT, Sobieszczyk ME,  
472 Huang Y, Wang HH, Sheng Z, Yuen K-Y, Ho DD: Striking Antibody Evasion Manifested  
473 by the Omicron Variant of SARS-CoV-2. bioRxiv 2021. [Preprint].  
474 doi:2021.2012.2014.472719

475 [20] Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,  
476 Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Bolland WH, Buchrieser J, Baele G,

477 Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina T, Marti J,  
478 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Lorie ES, REY F, Bruel T, Mouquet H,  
479 Andre E, Schwartz O: Considerable escape of SARS-CoV-2 variant Omicron to  
480 antibody neutralization. bioRxiv 2021. [Preprint]. doi:2021.2012.2014.472630  
481 [21] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall  
482 M, Groves N, O'Connell A-M, Simons D, Blomquist PB, Zaidi A, Nash S, Aziz NIBA,  
483 Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R,  
484 Ladhani SN, Ferguson N, Zambon M, Campbell CN, Brown K, Hopkins S, Chand M,  
485 Ramsay M, Bernal JL: Effectiveness of COVID-19 vaccines against the Omicron  
486 (B.1.1.529) variant of concern. medRxiv 2021. [Preprint]. doi:2021.2012.2014.21267615  
487 [22] Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: Reduced sensitivity  
488 of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv 2021.  
489 [Preprint]. doi:2021.2012.2017.21267961  
490 [23] Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, Scheepers C,  
491 Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z,  
492 Reedoy K, Cromer D, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim  
493 SSA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J, Lessells RJ, Moosa  
494 M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A: SARS-CoV-2 Omicron has  
495 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires  
496 ACE2 for infection. medRxiv 2021. [Preprint]. doi:2021.2012.2008.21267417  
497 [24] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An  
498 R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X,  
499 Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: B.1.1.529

500 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes.  
501 bioRxiv 2021. [Preprint]. doi:2021.2012.2007.470392  
502 [25] Hansen CH, Schelde AB, Moustsen-Helms IR, Emborg H-D, Krause TG, Moelbak  
503 K, Valentiner-Branth P, Institut TIDPGaSS: Vaccine effectiveness against SARS-CoV-2  
504 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2  
505 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021. [Preprint].  
506 doi:2021.2012.2020.21267966  
507 [26] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima  
508 N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata  
509 T, Chen IP, Ott M, Doudna JA: Omicron mutations enhance infectivity and reduce  
510 antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv 2021. [Preprint].  
511 doi:2021.2012.2020.21268048  
512 [27] Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Martin DP, Reddy ST,  
513 Dillner J, Karlsson Hedestam GB, Albert J, Murrell B: Variable loss of antibody potency  
514 against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv 2021. [Preprint].  
515 doi:2021.2012.2019.473354  
516 [28] Haveri A, Solastie A, Ekström N, Österlund P, Nohynek H, Nieminen T, Palmu AA,  
517 Melin M: Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA  
518 vaccination in health care workers and elderly subjects and response to a single dose in  
519 previously infected adults. medRxiv 2021. [Preprint]. doi:2021.2012.2022.21268273  
520 [29] Arien KK, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S, Pannus  
521 P, Martens GA, Van Esbroeck M, Goossens ME, Marchant A, Bartholomeeusen K,  
522 Desombere I: Three doses of the BNT162b2 vaccine confer neutralising antibody



523 capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern. medRxiv  
524 2021. [Preprint]. doi:2021.2012.2023.21268316

525 [30] Willett BJ, Grove J, MacLean O, Wilkie C, Logan N, De Lorenzo G, et al.: The  
526 hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change,  
527 vaccine escape and a switch in cell entry mechanism. medRxiv 2022. [Preprint].  
528 doi:2022.2001.2003.21268111

529 [31] Boschi C, Colson P, Bancod A, Moal V, La Scola B: Omicron variant escapes  
530 therapeutic mAbs contrary to eight prior main VOC. bioRxiv 2022. [Preprint].  
531 doi:2022.2001.2003.474769

532 [32] Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I,  
533 Uriu K, Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki  
534 Y, Minami R, Toya T, Sekiya N, Fukuhara T, Matsuura Y, Schreiber G, Ikeda T,  
535 Nakagawa S, Ueno T, Sato K: SARS-CoV-2 spike L452R variant evades cellular  
536 immunity and increases infectivity. Cell Host Microbe 2021, 29:1124-1136.e1111

537 [33] Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H,  
538 Wang M, Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y: The Impact of  
539 Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 2020,  
540 182:1284-1294 e1289

541 [34] Ulloa AC, Buchan SA, Daneman N, Brown KA: Early estimates of SARS-CoV-2  
542 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv  
543 2021. [Preprint]. doi:2021.2012.2024.21268382

544 [35] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG,  
545 Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender


546 N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-y,  
547 Parboosing R, Wadula J, Hussey H, Davies M-A, Boulle A, von Gottberg A, Cohen C:  
548 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South  
549 Africa. medRxiv 2021. [Preprint]. doi:2021.2012.2021.21268116  
550 [36] SARS-CoV-2 variants of concern and variants under investigation in England  
551 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron  
552 VOC-21NOV-01 (B.1.1.529) UK Health Security: UK Health Security, 2021.  
553 [37] Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R,  
554 Prince T, Brown JC, Zhou J, Screaton GR, Barclay WS, Owen A, Hiscox JA, Stewart  
555 JP: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B  
556 and Delta variants strains in a mouse model of severe COVID-19. bioRxiv 2021.  
557 [Preprint]. doi:2021.2012.2026.474085  
558 [38] Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, Raymenants J,  
559 André E, Weynand B, Dallemier K, Neyts J: The omicron (B.1.1.529) SARS-CoV-2  
560 variant of concern does not readily infect Syrian hamsters. bioRxiv 2021. [Preprint].  
561 doi:2021.2012.2024.474086  
562 [39] Diamond M, Peter H, Tadashi M, Kiyoko I-H, Shun I, Maki K, et al.: The SARS-  
563 CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and  
564 hamsters Nature Portfolio 2022. 29 December 2021. [Preprint].  
565 doi:<https://doi.org/10.21203/rs.3.rs-1211792/v1>  
566 [40] McMahan K, Giffin V, Tostanoski L, Chung B, Siamatu M, Suthar M, Halfmann P,  
567 Kawaoka Y, Piedra-Mora C, Martinot A, Kar S, Andersen H, Lewis MG, Barouch DH:

568 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv 2022.

569 [Preprint]. doi:2022.2001.2002.474743


570

571



572

573 **Figure 1** Epidemiologic curve showing five COVID-19 disease waves in Houston  
574 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-  
575 three-day moving average. Each of the five waves is shown in a different color. The first  
576 and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes.  
577 The Alpha VOC shown in the third wave, the Delta VOC shown in the fourth, and the  
578 Omicron VOC shown in the fifth wave indicate their numeric prominence in those  
579 waves. The figure should not be interpreted to mean that all cases in the third, fourth,  
580 and fifth waves were caused by Alpha, Delta, and Omicron VOCs, respectively. Rather,  
581 they are the dominant single VOCs causing disease in Houston Methodist system  
582 patients in those waves. The fifth wave shown includes data through December 20,  
583 2021. The figure was generated with Tableau version 2021.2.7 (Tableau Software, LLC,  
584 Seattle, WA), and is a modified version of one presented recently<sup>6</sup>. The curve is  
585 essentially superimposable on COVID-19 activity in all metropolitan Houston, Texas.



586

587 **Figure 2** Increase in Omicron frequency over time and distribution in metropolitan

588 Houston. The study time frame was November 27, 2021 through December 20, 2021.

589 **A:** Omicron logistic growth model. The estimated case doubling time is 1.8 days. **B:**

590 Cumulative increase in Omicron during the study period; y-axis is the cumulative

591 number of new COVID-19 Omicron cases. At the end of the study period, Omicron

592 caused 90% of all COVID-19 cases. **C – E:** Geospatial distribution of Omicron based on

593 home address zip code for each patient. **C:** November 27 – December 3; **D:** November

594 27 – December 10; **E:** November 27 – December 20. Note differences in heat map

595 scale for each panel. Figures were generated using Tableau version 2021.2.7. (Tableau

596 Software, LLC, Seattle, WA).

597 **Table 1. Summary of pertinent patient metadata for 4,470 unique patients infected**  
 598 **with Omicron or Alpha variants.**

	Omicron Variant	Alpha Variant	Total	Statistical Analysis
<b>No. (%) with data</b>	1313 (29.4%)	3157 (70.6%)	4470	
<b>Patient Characteristics</b>				
Median Age (Years)	39.2	50.0	46.8	$P < 0.0001$ Mann-Whitney
Female	763 (58.1%)	1622 (51.4%)	2385 (53.4%)	$P < 0.0001$ Fisher's exact test
Male	550 (41.9%)	1535 (48.6%)	2085 (46.6%)	
<b>Ethnicity</b>				
Caucasian	406 (31.0%)	1241 (39.5%)	1647 (37.0%)	$P < 0.0001$ Chi-square
Hispanic or Latino	230 (17.6%)	945 (30.1%)	1175 (26.4%)	
Black	544 (41.6%)	732 (23.3%)	1276 (28.7%)	
Asian	49 (3.7%)	123 (3.9%)	172 (3.9%)	
Other	7 (0.5%)	32 (1.0%)	39 (0.9%)	
Unavailable	77 (5.9%)	84 (2.7%)	161 (3.6%)	
<b>BMI</b>				
Median BMI	28.6	30.5	30.0	$P < 0.0001$ Mann-Whitney
<b>Admission Data</b>				
Admitted	193 (14.7%)	1721 (54.5%)	1914 (42.8%)	$P < 0.0001$ Fisher's exact test  Odds Ratio: 0.144 (95% CI 0.122- 0.170)
Not Admitted	1120 (85.3%)	1436 (45.5%)	2556 (57.2%)	
Median LOS (Days) (Discharged patients only)	3.0	5.1	5.0	$P < 0.0001$ Mann-Whitney
<b>Max Respiratory Support</b>				
ECMO	1 (0.5%)	7 (0.4%)	8 (0.4%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	10 (5.2%)	144 (8.4%)	154 (8.0%)	

Non-Invasive Ventilation	16 (8.3%)	164 (9.5%)	180 (9.4%)	
High Flow Oxygen	18 (9.3%)	364 (21.2%)	382 (20.0%)	
Low Flow Oxygen	60 (31.1%)	722 (42.0%)	782 (40.9%)	
Room Air	88 (45.6%)	320 (18.6%)	408 (21.3%)	
<b>Mortality</b>				
Alive	1302 (99.2%)	2987 (94.6%)	4289 (96.0%)	$P < 0.0001$
Deceased	11 (0.8%)	170 (5.4%)	181 (4.0%)	Fisher's exact test
				Odds Ratio: 0.148 (95% CI 0.080- 0.274)
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	19.2 n=519	22.4 n=1050	n=1569	$P < 0.0001$ Mann-Whitney
Hologic Panther	22.0 n=88	24.2 n=359	n=447	$P = .0950$ Mann-Whitney
<b>Vaccine</b>				
Not Fully Vaccinated	638 (48.6%)	3056 (96.8%)	3694 (82.6%)	$P < 0.0001$
Fully Vaccinated	675 (51.4%)	101 (3.2%)	776 (17.4%)	Fisher's exact test
				Odds Ratio: 32.012 (95% CI 25.541- 40.123)

599 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

600 **Table 2. Summary of pertinent patient metadata for 16,995 unique patients**  
 601 **infected with Omicron or Delta variants.**

	Omicron Variant	Delta Variant	Total	Statistical Analysis
<b>No. (%) with data</b>	1313 (7.7%)	15682 (92.3%)	16995	
<b>Patient Characteristics</b>				
Median Age (Years)	39.2	48.2	47.5	$P < 0.0001$ Mann-Whitney
Female	763 (58.1%)	8109 (51.7%)	8872 (52.2%)	$P = 0.0001$ Fisher's exact test
Male	550 (41.9%)	7573 (48.3%)	8123 (47.8%)	
<b>Ethnicity</b>				
Caucasian	406 (30.9%)	6874 (43.8%)	7280 (42.8%)	$P < 0.0001$ Chi-square
Hispanic or Latino	230 (17.5%)	4166 (26.6%)	4396 (25.9%)	
Black	544 (41.4%)	3450 (22.0%)	3994 (23.5%)	
Asian	49 (3.7%)	527 (3.4%)	576 (3.4%)	
Other	7 (0.5%)	112 (0.7%)	119 (0.7%)	
Unavailable	77 (5.9%)	553 (3.5%)	630 (3.7%)	
<b>BMI</b>				
Median BMI	28.6	29.5	29.5	$P = 0.0001$ Mann-Whitney
<b>Admission Data</b>				
Admitted	193 (14.7%)	6749 (43.0%)	6942 (40.8%)	$P < 0.0001$ Fisher's exact test  Odds Ratio: 0.228 (95% CI 0.195- 0.267)
Not Admitted	1120 (85.3%)	8933 (57.0%)	10053 (59.2%)	
Median LOS (Days) (Discharged patients only)	3.0	5.4	5.3	$P < 0.0001$ Mann-Whitney
<b>Max Respiratory Support</b>				
ECMO	1 (0.5%)	19 (0.3%)	20 (0.3%)	$P < 0.0001$ Chi-square
Mechanical Ventilation	10 (5.2%)	723 (10.7%)	733 (10.6%)	



Non-Invasive Ventilation	16 (8.3%)	638 (9.5%)	654 (9.4%)	
High Flow Oxygen	18 (9.3%)	1785 (26.4%)	1803 (26.0%)	
Low Flow Oxygen	60 (31.1%)	2282 (33.8%)	2342 (33.7%)	
Room Air	88 (45.6%)	1302 (19.3%)	1390 (20.0%)	
<b>Mortality</b>				
Alive	1302 (99.2%)	14855 (94.7%)	16157 (95.1%)	$P < 0.0001$
Deceased	11 (0.8%)	827 (5.3%)	838 (4.9%)	Fisher's exact test
				Odds Ratio: 0.152 (95% CI 0.083- 0.276)
<b>Median PCR Cycle Threshold</b>				
Abbott Alinity	19.2 n=519	21.43 n=5102	n=5621	$P < 0.0001$ Mann-Whitney
Hologic Panther	22.0 n=88	22.6 n=1295	n=1383	$P = .8987$ Mann-Whitney
<b>Vaccine</b>				
No vaccine	584 (44.5%)	11387 (72.6%)	11971 (70.4%)	$P < 0.0001$
>7 days past 1st Vaccine	54 (4.1%)	492 (3.1%)	546 (3.2%)	Chi-square
>14 days past 2nd Vaccine	535 (40.7%)	3665 (23.4%)	4200 (24.7%)	
>14 days past 3rd Vaccine	140 (10.7%)	138 (0.9%)	278 (1.6%)	

602 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay